Incyte Corporation (NASDAQ:INCY) EVP Reid M. Huber sold 696 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $98.01, for a total value of $68,214.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Incyte Corporation (NASDAQ INCY) traded up $0.03 during trading hours on Wednesday, reaching $93.71. The company had a trading volume of 1,430,700 shares, compared to its average volume of 1,918,704. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01. Incyte Corporation has a fifty-two week low of $93.49 and a fifty-two week high of $153.15.
Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.11. The business had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. Incyte’s revenue was up 41.6% compared to the same quarter last year. During the same period last year, the firm posted $0.19 earnings per share. equities analysts predict that Incyte Corporation will post -1.33 EPS for the current fiscal year.
INCY has been the topic of several recent research reports. Raymond James Financial upgraded Incyte from a “market perform” rating to an “outperform” rating and set a $159.00 price objective on the stock in a research report on Monday, September 11th. J P Morgan Chase & Co restated a “buy” rating and issued a $149.00 price target on shares of Incyte in a research report on Thursday, August 31st. Oppenheimer restated a “hold” rating and issued a $135.00 price target on shares of Incyte in a research report on Thursday, August 31st. BMO Capital Markets restated an “outperform” rating and issued a $172.00 price target on shares of Incyte in a research report on Monday, August 28th. Finally, Argus restated a “buy” rating and issued a $150.00 price target on shares of Incyte in a research report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $145.65.
COPYRIGHT VIOLATION NOTICE: “Incyte Corporation (INCY) EVP Reid M. Huber Sells 696 Shares of Stock” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/12/06/incyte-corporation-incy-evp-reid-m-huber-sells-696-shares-of-stock.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.